The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ERIC 2024 | A model including CD49d expression to predict outcomes in patients with CLL treated with ibrutinib
Valter Gattei, MD, University of Eastern Piedmont, Vercelli, Italy, discusses a revised 4-factor model including CD49d expression to predict outcomes in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib. Overexpression of CD49d in these patients is associated with shorter progression-free survival (PFS), and the updated model includes CD49d, beta-2 microglobulin, prior therapies, and p53 disruptions. This interview took place at the 2024 European Research Initiative on CLL (ERIC) Meeting in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
